Bank of America Corp. Begins Coverage on Zoetis Inc. (ZTS)
Several other analysts have also recently commented on the stock. Jefferies Group reiterated a buy rating and issued a $60.00 price target on shares of Zoetis in a research note on Wednesday, September 14th. Argus upped their target price on shares of Zoetis from $54.00 to $58.00 and gave the company a below average rating in a research report on Friday, September 9th. Credit Suisse Group AG restated a focus list rating and set a $60.00 target price on shares of Zoetis in a research report on Wednesday, September 7th. Guggenheim restated a positive rating and set a $60.00 target price on shares of Zoetis in a research report on Monday, August 22nd. Finally, Citigroup Inc. upped their target price on shares of Zoetis from $50.00 to $53.00 and gave the company a neutral rating in a research report on Thursday, August 4th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $55.27.
Shares of Zoetis (NYSE:ZTS) opened at 52.31 on Thursday. The stock has a market capitalization of $25.90 billion, a price-to-earnings ratio of 40.74 and a beta of 1.00. The firm has a 50-day moving average of $51.27 and a 200 day moving average of $48.63. Zoetis has a one year low of $38.26 and a one year high of $52.64.
Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Wednesday, August 3rd. The company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.44 by $0.05. The business had revenue of $1.20 billion for the quarter, compared to analysts’ expectations of $1.17 billion. Zoetis had a net margin of 13.15% and a return on equity of 77.58%. The business’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.43 EPS. On average, equities research analysts predict that Zoetis will post $1.91 EPS for the current year.
In other Zoetis news, insider Andrew Fenton sold 13,870 shares of the company’s stock in a transaction dated Friday, September 2nd. The shares were sold at an average price of $51.25, for a total value of $710,837.50. Following the transaction, the insider now directly owns 17,719 shares in the company, valued at approximately $908,098.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Heidi C. Chen sold 32,097 shares of the company’s stock in a transaction dated Thursday, September 1st. The stock was sold at an average price of $50.98, for a total transaction of $1,636,305.06. Following the completion of the transaction, the insider now owns 46,060 shares in the company, valued at $2,348,138.80. The disclosure for this sale can be found here. Corporate insiders own 0.05% of the company’s stock.
Institutional investors have recently modified their holdings of the company. NEXT Financial Group Inc increased its position in shares of Zoetis by 9.5% in the second quarter. NEXT Financial Group Inc now owns 2,136 shares of the company’s stock worth $101,000 after buying an additional 186 shares in the last quarter. Kelly Lawrence W & Associates Inc. CA increased its position in shares of Zoetis by 113.4% in the second quarter. Kelly Lawrence W & Associates Inc. CA now owns 2,446 shares of the company’s stock worth $116,000 after buying an additional 1,300 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its position in shares of Zoetis by 22.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,566 shares of the company’s stock worth $121,000 after buying an additional 476 shares in the last quarter. NN Investment Partners Holdings N.V. bought a new position in shares of Zoetis during the first quarter worth approximately $118,000. Finally, Glenmede Trust Co. NA increased its position in shares of Zoetis by 4.4% in the second quarter. Glenmede Trust Co. NA now owns 2,950 shares of the company’s stock worth $139,000 after buying an additional 124 shares in the last quarter. Institutional investors and hedge funds own 93.12% of the company’s stock.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.